Plain-English translation of NCT05942053 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether vitamin K2 (menaquinone-7), taken as a daily capsule alongside a standard blood pressure medication called ramipril, can help slow kidney disease progression and protect bone health. People with early chronic kidney disease often develop problems with both their kidneys and bones at the same time. Researchers want to see if this medication, when added to existing treatment, can help control blood pressure, reduce protein loss in urine, and improve bone strength.
When kidneys don't work as well, they struggle to regulate minerals and hormones that keep bones strong and healthy. This medication has shown promise in laboratory studies for supporting both kidney and bone function, but doctors need to test whether it actually helps patients in real life.
You likely qualify if…
You likely don't qualify if…
You will take either vitamin K2 or a placebo pill once daily for 6 months, along with your ramipril blood pressure medication. You'll have monthly in-person visits to check your progress and give blood samples, plus weekly check-in phone calls to make sure you're taking your medication as prescribed. The study team will monitor your blood pressure, protein in your urine, and bone health markers throughout the trial.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Egypt